Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: Implication of leucocyte recruitment

Cancer Immunology, Immunotherapy

Volumn 61, Issue 11, 2012, Pages 2113-2123

  Dempe, Sebastian ^a,b   Lavie, Muriel ^b   Struyf, Sofie ^a,b   Bhat, Rauf ^b   Verbeke, Hannelien ^a   Paschek, Stephanie ^b   Berghmans, Nele ^a   Geibig, Renate ^b   Rommelaere, Jean ^b   Van Damme, Jo ^a   Dinsart, Christiane ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Chemokine; IL 2; Pancreatic carcinoma; Parvovirus

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKOCYTE MIGRATION; LYMPHOCYTE ACTIVATION; MONOCYTE; MOUSE; NATURAL KILLER CELL; NEWBORN; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TRANSGENE; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CHEMOKINE CCL7; CHEMOKINE CXCL10; FEMALE; H-1 PARVOVIRUS; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTES; LYMPHOCYTE ACTIVATION; MICE; MICE, NUDE; MONOCYTES; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PANCREATIC NEOPLASMS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871025600     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1279-4     Document Type: Article

References (49)

1. Schneider G, Schmid RM (2003) Genetic alterations in pancreatic carcinoma. Mol Cancer 2:15
2. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM (2003) A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 9(2):555-561
3. Petrulio CA, Kaufman HL (2006) Development of the PANVACVF vaccine for pancreatic cancer. Exp Rev Vac 5(1):9-19. doi: 10.1586/14760584.5.1.9
4. Gordon EM, Chan MT, Geraldino N, Lopez FF, Cornelio GH, Lorenzo CC 3rd, Levy JP, Reed RA, Liu L, Hall FL (2007) Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes. Int J Oncol 30(6):1297-1307
5. Chawla SP, Chua VS, Fernandez L, Quon D, Blackwelder WC, Gordon EM, Hall FL (2010) Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer. Mol Ther 18(2): 435-441. doi:10.1038/mt.2009.228
6. Fu X, Tao L, Li M, Fisher WE, Zhang X (2006) Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clin Cancer Res 12(10):3152-3157. doi:10.1158/1078-0432.ccr-06-0045
7. Kasuya H, Nishiyama Y, Nomoto S, Goshima F, Takeda S, Watanabe I, Nomura N, Shikano T, Fujii T, Kanazumi N, Nakao A (2007) Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. Cancer Gene Ther 14(6):533-542
8. Liu S-H, Davis A, Li Z, Ballian N, Davis E, Wang X-P, Fisher W, Brunicardi FC (2007) Effective ablation of pancreatic cancer cells in SCID mice using systemic adenoviral RIP-TK/GCV gene therapy. J Surg Res 141(1):45-52
9. Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I, Schlehofer JR, Raykov Z (2010) Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev. doi:10.1016/j.cytogfr.2010.02.011
10. Cornelis JJ, Becquart P, Duponchel N, Salome N, Avalosse BL, Namba M, Rommelaere J (1988) Transformation of human fibroblasts by ionizing radiation, a chemical carcinogen, or simian virus 40 correlates with an increase in susceptibility to the autonomous parvoviruses H-1 virus and minute virus of mice. J Virol 62(5):1679-1686
11. Dempe S, Stroh-Dege AY, Schwarz E, Rommelaere J, Dinsart C (2010) SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV. Int J Cancer 126(12):2914-2927. doi:10.1002/ijc.24992
12. Toolan HW, Rhode SL 3rd, Gierthy JF (1982) Inhibition of 7,12-dimethylbenz(a)anthracene-induced tumors in Syrian hamsters by prior infection with H-1 parvovirus. Cancer Res 42(7):2552-2555
13. Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, Dinsart C, Herrmann A, Balboni G, Rommelaere J, Raykov Z (2009) Improvement of gemcitabine-based therapy of pancreatic carcinoma bymeans of oncolytic parvovirusH-1PV.Clin Cancer Res 15(2):511-519. doi:10.1158/1078-0432.CCR-08-1088
14. Geletneky K, Kiprianova I, Ayache A, Koch R, Herrero YCM, Deleu L, Sommer C, Thomas N, Rommelaere J, Schlehofer JR (2010) Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. Neuro Oncol. doi:10.1093/neuonc/noq023
15. Cornelis JJ, Salome N, Dinsart C, Rommelaere J (2004) Vectors based on autonomous parvoviruses: novel tools to treat cancer? J Gene Med 6(Suppl 1):S193-S202. doi:10.1002/jgm.502
16. Parker JC, Collins MJ, Jr., Cross SS, Rowe WP (1970) Minute virus of mice. II. Prevalence, epidemiology, and occurrence as a contaminant of transplanted tumors. J Natl Cancer Inst 45(2):305-310
17. Kestler J, Neeb B, Struyf S, Van Damme J, Cotmore SF, D'Abramo A, Tattersall P, Rommelaere J, Dinsart C, Cornelis JJ (1999) Cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Hum Gene Ther 10(10):1619-1632. doi:10.1089/10430349950017626
18. Olijslagers S, Dege AY, Dinsart C, Voorhoeve M, Rommelaere J, Noteborn MH, Cornelis JJ (2001) Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin. Cancer Gene Ther 8(12):958-965
19. Enderlin M, Kleinmann EV, Struyf S, Buracchi C, Vecchi A, Kinscherf R, Kiessling F, Paschek S, Sozzani S, Rommelaere J, Cornelis JJ, Van Damme J, Dinsart C (2009) TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther 16(2):149-160
20. Haag A, Menten P, Van Damme J, Dinsart C, Rommelaere J, Cornelis JJ (2000) Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Hum Gene Ther 11(4):597-609. doi:10.1089/ 10430340050015789
21. Wetzel K, Struyf S, Van Damme J, Kayser T, Vecchi A, Sozzani S, Rommelaere J, Cornelis JJ, Dinsart C (2007) MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells. Int J Cancer 120(6):1364-1371. doi:10.1002/ijc.22421
22. Giese NA, Raykov Z, DeMartino L, Vecchi A, Sozzani S, Dinsart C, Cornelis JJ, Rommelaere J (2002) Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther 9(5):432-442. doi:10.1038/sj.cgt.7700457
23. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52(1):145-176
24. Kuehn R, Lelkes PI, Bloechle C, Niendorf A, Izbicki JR (1999) Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer. Pancreas 18(1):96-103
25. Monti P, Marchesi F, Reni M, Mercalli A, Sordi V, Zerbi A, Balzano G, Di Carlo V, Allavena P, Piemonti L (2004) A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Arch 445(3):236-247
26. Hussain F, Wang J, Ahmed R, Guest SK, Lam EW, Stamp G, El-Bahrawy M (2010) The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours. Cytokine 49(2):134-140. doi:10.1016/j.cyto.2009. 11.010
27. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP (2005) CXC chemokines in angiogenesis. Cytokine & growth factor reviews 16 (6):593-609. doi:10.1016/j.cytogfr.2005.04.007
28. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B (1996) Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184(3):963-969
29. Taub DD, Sayers TJ, Carter CR, Ortaldo JR (1995) Alpha and beta chemokines induce NK cell migration and enhance NKmediated cytolysis. J Immunol 155(8):3877-3888
30. Penna G, Sozzani S, Adorini L (2001) Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J Immunol 167(4):1862-1866
31. Luster AD, Leder P (1993) IP-10, a -C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 178(3):1057-1065
32. Pross HF, Lotzova E (1993) Role of natural killer cells in cancer. Nat Immun 12(4-5):279-292
33. Bhat R, Dempe S, Dinsart C, Rommelaere J (2011) Enhancement of NK cell anti-tumour responses using an oncolytic parvovirus. Int J Cancer 128(4):908-919. doi:10.1002/ijc.25415
34. Wrzesinski C, Tesfay L, Salome N, Jauniaux JC, Rommelaere J, Cornelis JJ, Dinsart C (2003) Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells. J Virol 77(6):3851-3858
35. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B (1996) Activation of NK cells by CC chemokines. Chemotaxis, Ca2 ? mobilization, and enzyme release. J Immunol 156(1): 322-327
36. Polentarutti N, Allavena P, Bianchi G, Giardina G, Basile A, Sozzani S, Mantovani A, Introna M (1997) IL-2-regulated expression of the monocyte chemotactic protein-1 receptor (CCR2) in human NK cells: characterization of a predominant 3.4-kilobase transcript containing CCR2B and CCR2A sequences. J Immunol 158(6):2689-2694
37. Natuk RJ, Welsh RM (1987) Chemotactic effect of human recombinant interleukin 2 on mouse activated large granular lymphocytes. J Immunol 139(8):2737-2743
38. Allavena P, Bianchi G, Zhou D, van Damme J, Jilek P, Sozzani S, Mantovani A (1994) Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol 24(12):3233-3236. doi:10.1002/eji.1830241249
39. Maghazachi AA, Skalhegg BS, Rolstad B, Al-Aoukaty A (1997) Interferon-inducible protein-10 and lymphotactin induce the chemotaxis and mobilization of intracellular calcium in natural killer cells through pertussis toxin-sensitive and -insensitive heterotrimeric G-proteins. FASEB J 11(10):765-774
40. Tannous BA, Kim D-E, Fernandez JL, Weissleder R, Breakefield XO (2005) Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 11(3):435-443
41. Van Damme J, Proost P, Lenaerts JP, Opdenakker G (1992) Structural and functional identification of two human, tumorderived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J Exp Med 176(1):59-65
42. Amano H, Amano E, Santiago-Raber ML, Moll T, Martinez-Soria E, Fossati-Jimack L, Iwamoto M, Rozzo SJ, Kotzin BL, Izui S (2005) Selective expansion of a monocyte subset expressing the CD11c dendritic cell marker in the Yaa model of systemic lupus erythematosus. Arthritis Rheum 52(9):2790-2798. doi:10.1002/art.21365
43. Lechmann M, Berchtold S, Hauber J, Steinkasserer A (2002) CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol 23(6):273-275
44. Cornelis JJ, Lang SI, Stroh-Dege AY, Balboni G, Dinsart C, Rommelaere J (2004) Cancer gene therapy through autonomous parvovirus-mediated gene transfer. Curr Gene Ther 4(3):249-261
45. Shaker MA, Younes HM (2009) Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy. J Pharm Sci 98(7):2268-2298. doi:10.1002/jps.21596
46. Wagner K, Schulz P, Scholz A, Wiedenmann B, Menrad A (2008) The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res 14(15):4951-4960. doi:10.1158/1078-0432.CCR-08-0157
47. Degrate L, Nobili C, Franciosi C, Caprotti R, Brivio F, Romano F, Leone BE, Trezzi R, Uggeri F (2009) Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients. Langenbecks Arch Surg 394(1):115-121. doi:10.1007/s00423-008-0393-4
48. Fioretti F, Fradelizi D, Stoppacciaro A, Ramponi S, Ruco L, Minty A, Sozzani S, Garlanda C, Vecchi A, Mantovani A (1998) Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J Immunol 161(1):342-346
49. Jia T, Serbina NV, Brandl K, Zhong MX, Leiner IM, Charo IF, Pamer EG (2008) Additive roles for MCP-1 and MCP-3 in CCR2-mediated recruitment of inflammatory monocytes during Listeria monocytogenes infection. J Immunol 180(10):6846-6853